ZGNX - Should Investors Buy GW Pharma Stock Right Now?
Most cannabis-related companies have seen their stock prices tumble over the past few months, but a few have been more resilient. Although GW Pharma (NASDAQ: GWPH) might not be a pot stock in the traditional sense, sales of the company's cannabidiol (CBD)-based drug, Epidiolex, have been growing at an impressive rate.
With the company's second CBD-based drug, Nabiximols, set to begin phase 3 trials soon, there's a lot of excitement surrounding GW Pharma right now. Some Wall Street analysts have recently revised their previous projections for the company, now predicting that GW's stock could end up doubling in the next year.
Is now the right time to buy GW Pharma? Let's find out.